2.2.0.7falseAcquisitions and Dispositions0202 - Disclosure - Acquisitions and Dispositionstruefalsefalsefalse1USDfalsefalseUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0$20biib_AcquisitionsAndDispositionsAbstractbiibfalsenadurationAcquisitions and Dispositions Abstract.falsefalsefalsefalsefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalsefalse00falsefalsefalsexbrli:stringItemTypestringAcquisitions and Dispositions Abstract.false31biib_AcquisitionsAndDispositionsTextBlockbiibfalsenadurationA textual description of the key elements that define a specific acquisition, disposal or detail of assets held for sale.falsefalsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabelfalse1falsefalsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 2 - biib:AcquisitionsAndDispositionsTextBlock-->
<div style="margin-left: 0%">
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent; text-align: left">
<tr>
<td width="3%"></td>
<td width="97%"></td>
</tr>
<tr valign="top">
<td>
<b><font style="font-family: 'Times New Roman', Times">2.  </font></b>
</td>
<td>
<b><font style="font-family: 'Times New Roman', Times">Acquisitions
and Dispositions</font></b>
</td>
</tr>
</table>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">
<b><i><font style="font-family: 'Times New Roman', Times">Biogen
Idec Hemophilia Inc. (formerly Syntonix Pharmaceuticals,
Inc.)</font></i></b>
</div>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
In connection with our acquisition of Biogen Idec Hemophilia
Inc. (BIH), formerly Syntonix Pharmaceuticals, Inc. (Syntonix),
in January 2007, we agreed to make additional future
consideration payments based upon the achievement of certain
milestone events associated with the development of BIH’s
lead product, long-acting recombinant Factor IX, a product for
the treatment of hemophilia B. In January 2010, we initiated
patient enrollment in a registrational stage study for Factor IX
which resulted in the achievement of one of those milestone
events. As a result of the achievement of this milestone, we
paid approximately $40.0 million to the former shareholders
of Syntonix. As the acquisition of BIH occurred prior to our
January 1, 2009 adoption of a new accounting standard for
business combinations, this acquisition continues to be
accounted for under previously issued guidance. Accordingly, we
recorded this payment as a charge to acquired in-process
research and development (IPR&D) within our consolidated
statements of income. For a more detailed description of this
acquisition, please read Note 2, <i>Acquisitions and
Dispositions </i>to our consolidated financial statements
included within our 2009
<font style="white-space: nowrap">Form 10-K.</font>
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Notefalsefalsefalseus-types:textBlockItemTypetextblockA textual description of the key elements that define a specific acquisition, disposal or detail of assets held for sale.No authoritative reference available.false12falseUnKnownUnKnownUnKnownfalsetrue